Percutaneous tricuspid valve therapies are being evaluated as an alternative to surgery for patients with severe tricuspid regurgitation who are at high surgical risk.
This review highlights the unmet clinical need and explores emerging percutaneous technologies for treating severe tricuspid regurgitation in high-risk surgical patients.
Moderate-to-severe tricuspid regurgitation (TR) affects ∼1.6 million patients in the USA, of whom only 8000 undergo tricuspid surgery annually; this results in an extremely large number of untreated patients with significant TR. Therefore, there is a large unmet clinical need for patients with severe TR who are not referred for conventional surgery, mainly due to expected high surgical risk. Percutaneous procedures are an attractive alternative to surgery for patients deemed to be high-risk surgical candidates. Whereas over the past few years, the development and clinical use of percutaneous approaches to the aortic valve and mitral valve have been widespread, few data are available about the feasibility and the efficacy of the percutaneous tricuspid valve treatment. This review will explore the available technologies, which are today under evaluation and the preliminary clinical results.
Taramasso et al. (Thu,) conducted a review in Moderate-to-severe tricuspid regurgitation. Percutaneous tricuspid valve therapies was evaluated. Percutaneous tricuspid valve therapies are being evaluated as an alternative to surgery for patients with severe tricuspid regurgitation who are at high surgical risk.